Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) have earned an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.
Brokerages have set a twelve-month consensus price objective of $255.00 for the company and are forecasting that the company will post $2.13 EPS for the current quarter, according to Zacks. Zacks has also assigned Mesa Laboratories an industry rank of 149 out of 256 based on the ratings given to its competitors.
MLAB has been the subject of a number of analyst reports. BidaskClub upgraded shares of Mesa Laboratories from a “sell” rating to a “hold” rating in a research note on Friday, March 29th. Sidoti initiated coverage on shares of Mesa Laboratories in a research note on Wednesday, March 13th. They issued a “neutral” rating for the company. TheStreet upgraded shares of Mesa Laboratories from a “c” rating to a “b-” rating in a research note on Friday, February 8th. Zacks Investment Research upgraded shares of Mesa Laboratories from a “hold” rating to a “buy” rating and set a $256.00 price objective for the company in a research note on Wednesday, April 3rd. Finally, ValuEngine cut shares of Mesa Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday, April 23rd.
Mesa Laboratories (NASDAQ:MLAB) last posted its earnings results on Monday, February 4th. The medical instruments supplier reported $1.69 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.68 by $0.01. The company had revenue of $26.68 million during the quarter, compared to the consensus estimate of $25.80 million. Mesa Laboratories had a net margin of 9.98% and a return on equity of 23.53%. On average, equities research analysts predict that Mesa Laboratories will post 5.1 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 31st will be paid a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.27%. The ex-dividend date is Thursday, May 30th. Mesa Laboratories’s payout ratio is 10.36%.
In related news, Director Robert V. Dwyer sold 5,575 shares of the company’s stock in a transaction on Friday, February 15th. The shares were sold at an average price of $232.00, for a total transaction of $1,293,400.00. Following the completion of the transaction, the director now directly owns 53,913 shares in the company, valued at approximately $12,507,816. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director David M. Kelly sold 684 shares of the company’s stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $230.00, for a total transaction of $157,320.00. Following the transaction, the director now owns 3,584 shares of the company’s stock, valued at $824,320. The disclosure for this sale can be found here. Insiders sold 19,842 shares of company stock valued at $4,607,649 over the last 90 days. 15.00% of the stock is owned by corporate insiders.
A number of large investors have recently added to or reduced their stakes in MLAB. Atlanta Capital Management Co. L L C acquired a new position in Mesa Laboratories during the 4th quarter valued at $26,142,000. Ranger Investment Management L.P. raised its stake in Mesa Laboratories by 75.4% during the 4th quarter. Ranger Investment Management L.P. now owns 157,019 shares of the medical instruments supplier’s stock valued at $32,721,000 after purchasing an additional 67,492 shares during the last quarter. BlackRock Inc. raised its stake in Mesa Laboratories by 10.2% during the 4th quarter. BlackRock Inc. now owns 252,580 shares of the medical instruments supplier’s stock valued at $52,634,000 after purchasing an additional 23,384 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in Mesa Laboratories by 38.1% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 80,814 shares of the medical instruments supplier’s stock valued at $16,841,000 after purchasing an additional 22,305 shares during the last quarter. Finally, Bank of America Corp DE raised its stake in Mesa Laboratories by 422.6% during the 4th quarter. Bank of America Corp DE now owns 16,487 shares of the medical instruments supplier’s stock valued at $3,436,000 after purchasing an additional 13,332 shares during the last quarter. Hedge funds and other institutional investors own 75.10% of the company’s stock.
Mesa Laboratories Company Profile
Mesa Laboratories, Inc designs, manufactures, and markets quality control instruments and disposable products. The company's Instruments segment offers data loggers, which are precision instruments used in critical manufacturing, quality control, and validation applications; medical meters and calibration solutions used to test various parameters of the dialysis fluid, and the calibration and operation of the dialysis machine; gas flow calibration and air sampling equipment that are used for industrial hygiene assessments, calibration of gas metering equipment, and environmental air monitoring; and torque testing systems used for measure bottle cap tightness.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.